<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470128</url>
  </required_header>
  <id_info>
    <org_study_id>HSK21542-202</org_study_id>
    <nct_id>NCT04470128</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of HSK21542 Injection for Analgesia in Subjects Undergoing Colonoscopy</brief_title>
  <official_title>A Multi-center, Randomized, Two-stage, Phase II Clinical Study Evaluating the Efficacy and Safety of HSK21542 Injection for Analgesia in Subjects Undergoing Diagnostic or Therapeutic Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, two-stage, phase II clinical study .The main objective is&#xD;
      to evaluate the safety and tolerability of HSK21542 injection for analgesia in patients&#xD;
      undergoing colonoscopy, and, combining the pharmacodynamic (PD) and pharmacokinetic (PK)&#xD;
      characteristics&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Stage I is open-label,Stage II is double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of HSK21542 injection for analgesia in subjects undergoing colonoscopy.</measure>
    <time_frame>From the first dose of the study drug to removal of colonoscope on day 1</time_frame>
    <description>Rate of successful colonoscopies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of HSK21542 injection for analgesia in subjects undergoing colonoscopy.</measure>
    <time_frame>From screening up to 3 weeks</time_frame>
    <description>The incidence and severity of adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of occurrences of BPS-NI score of &gt; 3: The ratio of subjects with BPS-NI scores of &gt; 3 for 0, 1, 2, 3, or more times from the insertion to the removal of colonoscope</measure>
    <time_frame>From administration until 24 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: Systolic and Diastolic Blood Pressure</measure>
    <time_frame>From screening up to the 3 weeks</time_frame>
    <description>Vital signs (Systolic and Diastolic Blood Pressure) will be collected in subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of propofol used</measure>
    <time_frame>From the first dose of the study drug to removal of colonoscope on day 1</time_frame>
    <description>The total dose used during the induction period, maintenance period, and the entire study process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to full recovery</measure>
    <time_frame>On day 1</time_frame>
    <description>The time from the removal of colonoscope to when the subject opens his/her eyes and can tell his/her date of birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>On day 1</time_frame>
    <description>The time from the removal of colonoscope to the occurrence of 3 consecutive Aldrete score of ≥ 9</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Stage I: HSK21542 0.5 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage I: HSK21542 1 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II : HSK21542 0.5 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II : HSK21542 1 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II : fentanyl 1 μg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage I: HSK21542 0.5 μg/kg</intervention_name>
    <description>After the completion of the administration of study drug (2, 15, and 30 min), propofol is initially intravenously injected at 0.3 mg/kg</description>
    <arm_group_label>Stage I: HSK21542 0.5 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage I: HSK21542 1 μg/kg</intervention_name>
    <description>After the completion of the administration of study drug (2, 15, and 30 min), propofol is initially intravenously injected at 0.3 mg/kg</description>
    <arm_group_label>Stage I: HSK21542 1 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542 0.5 μg/kg</intervention_name>
    <description>The dose and time of administration of the investigational product will be adjusted appropriately based on the results of stage I, with corresponding protocol amendments.</description>
    <arm_group_label>Stage II : HSK21542 0.5 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542 1 μg/kg</intervention_name>
    <description>The dose and time of administration of the investigational product will be adjusted appropriately based on the results of stage I, with corresponding protocol amendments.</description>
    <arm_group_label>Stage II : HSK21542 1 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl 1 μg/kg</intervention_name>
    <description>The dose and time of administration of the investigational product will be adjusted appropriately based on the results of stage I, with corresponding protocol amendments.</description>
    <arm_group_label>Stage II : fentanyl 1 μg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects undergoing diagnostic and/or therapeutic colonoscopy with an estimated&#xD;
             operation duration of 15-45 min;&#xD;
&#xD;
          2. Aged ≥ 18 and ≤ 75 years old, with no restriction on gender;&#xD;
&#xD;
          3. American Society of Anesthesiologists (ASA) Class I-II;&#xD;
&#xD;
          4. BMI ≥ 18 kg/m^2 and ≤ 30 kg/m^2;&#xD;
&#xD;
          5. During screening and at baseline: respiratory rate ≥ 10 and ≤ 24 bpm; SpO2 ≥ 95%&#xD;
             during inhalation; SBP ≥ 90 mmHg; DBP ≥ 50 mmHg; HR ≥ 50 and ≤ 100 bpm;&#xD;
&#xD;
          6. Subjects with intelligence and consciousness sufficient enough for cooperating with&#xD;
             the study;&#xD;
&#xD;
          7. Capable of understanding the procedure and method of this study, willing to sign an&#xD;
             informed consent form and to complete this study in strict accordance with the study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients having contraindications to deep sedation/general anesthesia or a history of&#xD;
             past sedation/anesthesia accidents;&#xD;
&#xD;
          2. Patients with past history of allergy or contraindications to opioids, their rescue&#xD;
             medications, and propofol;&#xD;
&#xD;
          3. Medical history or evidence of any of the following prior to screening/at baseline,&#xD;
             which may increase sedation/anesthesia risk:&#xD;
&#xD;
               1. History of cardiovascular diseases: uncontrolled hypertension (systolic blood&#xD;
                  pressure [SBP] ≥ 170 mmHg and/or diastolic blood pressure [DBP] ≥ 105 mmHg&#xD;
                  without treatment, or SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg after antihypertensive&#xD;
                  treatment), severe arrhythmia, heart failure, Adams-Stokes syndrome, New York&#xD;
                  Heart Association (NYHA) Class ≥ III, severe superior vena cava syndrome,&#xD;
                  pericardial effusion, acute myocardial ischemia, unstable angina, myocardial&#xD;
                  infarction within 6 months before screening, history of tachycardia/bradycardia&#xD;
                  requiring medical treatment, II-III degree atrioventricular block (excluding&#xD;
                  patients with pacemakers);&#xD;
&#xD;
               2. History of respiratory system disorders: respiratory insufficiency, history of&#xD;
                  obstructive pulmonary disease, history of bronchospasm requiring treatment within&#xD;
                  3 months prior to screening, acute respiratory tract infection with obvious&#xD;
                  symptoms such as fever, wheezing, nasal obstruction, and cough within 1 week&#xD;
                  prior to baseline;&#xD;
&#xD;
               3. History of neurological and psychiatric disorders: craniocerebral injury,&#xD;
                  possible convulsions, myoclonus, intracranial hypertension, cerebral aneurysms,&#xD;
                  history of cerebrovascular accidents; schizophrenia, mania, insanity, long-term&#xD;
                  use of psychotropic drugs, and history of cognitive dysfunction; history of&#xD;
                  depression, anxiety, and epilepsy, etc.;&#xD;
&#xD;
               4. History of gastrointestinal disorders: gastrointestinal retention, active&#xD;
                  hemorrhage, or conditions that may lead to reflux and aspiration;&#xD;
&#xD;
               5. History of alcohol abuse within 3 months prior to screening, with abuse defined&#xD;
                  as average of &gt; 2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor&#xD;
                  with 40% alcohol or 150 mL wine);&#xD;
&#xD;
               6. History of drug abuse within 3 months prior to screening;&#xD;
&#xD;
               7. History of blood donation or blood loss of ≥ 400 mL within 3 months prior to&#xD;
                  screening;&#xD;
&#xD;
          4. Patients with the following airway management risks:&#xD;
&#xD;
               1. Asthma history, and stridor;&#xD;
&#xD;
               2. Sleep apnea syndrome;&#xD;
&#xD;
               3. History or family history of malignant hyperthermia;&#xD;
&#xD;
               4. History of failed tracheal intubation;&#xD;
&#xD;
               5. Judged by the investigator to have difficult airway or judged as difficult&#xD;
                  tracheal intubation (modified Mallampati class IV) at screening;&#xD;
&#xD;
          5. In receipt of any one of the following medications or treatments at screening:&#xD;
&#xD;
               1. A time between the last use of opioid and non-opioid (such as paracetamol,&#xD;
                  aspirin [daily dose &gt; 100 mg], indomethacin, diclofenac, parecoxib sodium, and&#xD;
                  other non-steroidal anti-inflammatory drugs) analgesics and randomization of&#xD;
                  shorter than 5 half-lives of the drug or the duration of the drug's efficacy&#xD;
                  (whichever is longer);&#xD;
&#xD;
               2. Longer than 10 days of continuous use of opioid analgesics for any reason within&#xD;
                  3 months prior to screening;&#xD;
&#xD;
               3. Use of drugs that affect the analgesic effect within 14 days before&#xD;
                  randomization, including but not limited to: sedative-hypnotics (benzodiazepines&#xD;
                  [triazolam, diazepam, and midazolam] and non-benzodiazepines [zolpidem,&#xD;
                  zopiclone, zaleplon]), sedative-anesthetics (sevoflurane, nitrous oxide,&#xD;
                  ketamine, and etomidate), glucocorticoids (dexamethasone hydrochloride and&#xD;
                  methylprednisolone), antiepileptics (carbamazepine and sodium valproate),&#xD;
                  anxiolytics (chlordiazepoxide), antidepressants (imipramine and amitriptyline),&#xD;
                  and Chinese herbal medicines or Chinese patent medicines with analgesic and&#xD;
                  sedative effects;&#xD;
&#xD;
               4. A time between randomization and the last use of diuretics and compound drugs&#xD;
                  containing diuretics of shorter than 5 half-lives of the drug or the duration of&#xD;
                  the drug's efficacy (whichever is longer);&#xD;
&#xD;
          6. Patient whose laboratory parameters measured at screening reach the following criteria&#xD;
             and are verified through reexamination:&#xD;
&#xD;
               1. WBC &lt; 3.0 × 10^9/L;&#xD;
&#xD;
               2. Platelet count &lt; 80 × 10^9/L;&#xD;
&#xD;
               3. Hemoglobin &lt; 80 g/L;&#xD;
&#xD;
               4. Prothrombin time &gt; 1.5 × ULN;&#xD;
&#xD;
               5. Activated partial thromboplastin time &gt; 1.5 × ULN;&#xD;
&#xD;
               6. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 2 × ULN;&#xD;
&#xD;
               7. Total bilirubin &gt; 1.5 × ULN;&#xD;
&#xD;
               8. Blood creatinine &gt; 1.5 × ULN;&#xD;
&#xD;
          7. Having participated in other drug clinical trials within 3 months prior to screening&#xD;
             (defined as having received investigational product or placebo);&#xD;
&#xD;
          8. Pregnant or breastfeeding females: women or men of child-bearing potential who are&#xD;
             unwilling to use contraception during the trial; subjects who are planning pregnancy&#xD;
             within 3 months after the trial (including male subjects);&#xD;
&#xD;
          9. Subject judged by the investigator to have any other factors unsuitable for&#xD;
             involvement in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liu xiao</last_name>
    <phone>15921176768</phone>
    <email>liux1@haisco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wang xiao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

